The global glycomics market was valued at $512.38 million in 2014. This market is expected to grow at a CAGR of 12.62% to reach $928.11 million in 2019, According to the New Study on ASDReports

Wednesday 8 October 2014, Amsterdam

The global glycomics market is segmented on the basis of applications, end users and products. By application, the market is divided into diagnostics; drug discovery and development; immunology; oncology, and other applications. Of these, the drug discovery and development applications segment accounted for the largest share of the global glycomics enzymes, instruments, kits and reagents market in 2014. The end-user segments included in this report are academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies .By products, the market is segmented into enzymes, instruments, kits, and reagents.

The enzymes product segment is further subsegmented into glycosidases; glycosyl transferases; neuraminidases; sialyltransferases; and other enzymes.Of these, the glycosidases subsegment held the largest share of the global glycomics enzymes market in 2014, and is poised to grow at the highest CAGR between 2012 and 2019. The instrument segment is further subsegmented into antibody arrays; High-Performance Liquid Chromatography (HPLC); lectin arrays; MALDI-TOF; mass spectrometers; and other glycomics instruments. The kits product segment is further subsegmented into glycan labeling kits; glycan purification kits; glycan release kits; and other glycomics kits. The reagents segment is further subsegmented into glycoproteins; monosaccharaides; oligosaccharides; and other glycomics reagents.

The geographic segments included in this report are Asia, Europe, North America, and Rest of the World (RoW).The Asian segment is further divided into China, India, Japan, and Rest of Asia. Europe is divided into France, Germany, Italy, Spain, the U.K., and Rest of Europe. North America includes Canada, and the U.S. RoW encompasses the Middle East and Africa, Pacific and Oceania, and South America.

An increase inR&D expenditure by pharmaceutical and biotech companies and government support for the biotechnology industry will be the two most important growth drivers for this market in the forecast period (2012–2019). For instance, the Chinese government increased its basic research investment by 26% from 2011 to 2012 and decided to put more than $300 billion into biotechnology between 2012 and 2017. Investments of this nature will aid the growth of the glycomics market.

The major players in this market are Agilent Technologies (U.S.), Bruker Corp. (U.S.), Danaher Corp. (U.S.), New England Biolabs (U.S.), Prozyme, Inc. (U.S.), Shimadzu Corp. (Japan), Sigma-Aldrich Corp. (U.S.), Takara Bio (Japan), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S.), among others.